📊 IMVT Key Takeaways
Is Immunovant, Inc. (IMVT) a Good Investment?
Immunovant is a pre-commercial or early-stage biotech burning cash at an unsustainable rate, with operating losses of $505.4M against only $24.9M revenue. Despite strong 229% YoY revenue growth and excellent liquidity ($902.1M cash), the company is depleting reserves at ~$407.3M annually with no visible path to profitability, providing only ~2 years of runway at current burn rates.
Immunovant has a fortress balance sheet with nearly $1B in cash, negligible liabilities, and no debt, providing a multi‑year runway. However, fundamentals show minimal revenue, extremely negative margins, and heavy operating cash burn with no clear path to profitability yet. Wait for evidence of sustainable revenue and disciplined OpEx before reassessing.
Why Buy Immunovant, Inc. Stock? IMVT Key Strengths
- Revenue growth of 229% YoY indicates successful early commercialization or product adoption
- Exceptional liquidity with $902.1M cash and 9.09x current ratio provides operational runway
- Debt-free balance sheet (0.00x debt/equity) eliminates financial distress risk near-term
- Robust cash position (~$995M) and zero debt
- Exceptional liquidity (current/quick ratio 15.7x)
- Triple‑digit YoY revenue growth off a small base
IMVT Stock Risks: Immunovant, Inc. Investment Risks
- Operating losses of $505.4M with -2025.8% operating margin indicates severe unprofitability and unsustainable burn
- Cash burn of $407.3M annually will deplete reserves in approximately 2.2 years without profitability or financing
- Fundamental business model challenged: company burning 20x its revenue in operating costs with no clear profitability timeline
- Severe unprofitability with deeply negative operating and net margins
- High cash burn (FCF -$312M) implying future dilution risk when runway shortens
- Revenue base is small and potentially non‑recurring; no proven gross margin profile
Key Metrics to Watch
- Quarterly revenue growth rate and gross margin expansion trajectory
- Operating cash burn rate trend and cash runway remaining
- Path to operating profitability or evidence of margin improvement trajectory
- Quarterly operating cash burn and cash runway (cash/OCF)
- R&D and SG&A trends vs. milestone progress; revenue recurrence/composition
Immunovant, Inc. (IMVT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.09x current ratio provides a solid financial cushion.
IMVT Profit Margin, ROE & Profitability Analysis
IMVT vs Healthcare Sector: How Immunovant, Inc. Compares
How Immunovant, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immunovant, Inc. Stock Overvalued? IMVT Valuation Analysis 2026
Based on fundamental analysis, Immunovant, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immunovant, Inc. Balance Sheet: IMVT Debt, Cash & Liquidity
IMVT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immunovant, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.88 indicates the company is currently unprofitable.
IMVT Revenue Growth, EPS Growth & YoY Performance
Immunovant, Inc. Dividends, Buybacks & Capital Allocation
IMVT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immunovant, Inc. (CIK: 0001764013)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMVT
What is the AI rating for IMVT?
Immunovant, Inc. (IMVT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMVT's key strengths?
Claude: Revenue growth of 229% YoY indicates successful early commercialization or product adoption. Exceptional liquidity with $902.1M cash and 9.09x current ratio provides operational runway. ChatGPT: Robust cash position (~$995M) and zero debt. Exceptional liquidity (current/quick ratio 15.7x).
What are the risks of investing in IMVT?
Claude: Operating losses of $505.4M with -2025.8% operating margin indicates severe unprofitability and unsustainable burn. Cash burn of $407.3M annually will deplete reserves in approximately 2.2 years without profitability or financing. ChatGPT: Severe unprofitability with deeply negative operating and net margins. High cash burn (FCF -$312M) implying future dilution risk when runway shortens.
What is IMVT's revenue and growth?
Immunovant, Inc. reported revenue of $24.9M.
Does IMVT pay dividends?
Immunovant, Inc. does not currently pay dividends.
Where can I find IMVT SEC filings?
Official SEC filings for Immunovant, Inc. (CIK: 0001764013) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMVT's EPS?
Immunovant, Inc. has a diluted EPS of $-2.77.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMVT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Immunovant, Inc. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMVT stock overvalued or undervalued?
Valuation metrics for IMVT: ROE of -59.3% (sector avg: 15%), net margin of -2,026.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMVT stock in 2026?
Our dual AI analysis gives Immunovant, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMVT's free cash flow?
Immunovant, Inc.'s operating cash flow is $-407.3M, with capital expenditures of $8.0K. FCF margin is -1,632.7%.
How does IMVT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,026.6% (avg: 12%), ROE -59.3% (avg: 15%), current ratio 9.09 (avg: 2).